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ABSTRACT: Sepsis is a systemic inflammatory disease resulting from an infection. This disorder affects 750 000 people annually in the United
States and has a 62% rehospitalization rate. Septic symptoms range from typical flu-like symptoms (eg, headache, fever) to a multifactorial
syndrome known as sepsis-associated encephalopathy (SAE). Patients with SAE exhibit an acute altered mental status and often have higher
mortality and morbidity. In addition, many sepsis survivors are also burdened with long-term cognitive impairment. The mechanisms through
which sepsis initiates SAE and promotes long-term cognitive impairment in septic survivors are poorly understood. Due to its unique role as an
interface between the brain and the periphery, numerous studies support a regulatory role for the blood-brain barrier (BBB) in the progression
of acute and chronic brain dysfunction. In this review, we discuss the current body of literature which supports the BBB as a nexus which
integrates signals from the brain and the periphery in sepsis. We highlight key insights on the mechanisms that contribute to the BBB’s role
in sepsis which include neuroinflammation, increased barrier permeability, immune cell infiltration, mitochondrial dysfunction, and a potential
barrier role for tissue non-specific alkaline phosphatase (TNAP). Finally, we address current drug treatments (eg, antimicrobials and intravenous
immunoglobulins) for sepsis and their potential outcomes on brain function. A comprehensive understanding of these mechanisms may enable
clinicians to target specific aspects of BBB function as a therapeutic tool to limit long-term cognitive impairment in sepsis survivors.
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Introduction

the acute phase of sepsis. Multiple pathways have been investigated for their contribution to the sepsis-associated compromise of the BBB.2,3 This review integrates current clinical
knowledge of sepsis with mechanistic insights from both clinical studies and preclinical animal models of sepsis. The overall
goal of this review is to understand how sepsis pathophysiology
perturbs the integral functions of the cells and proteins that
comprise the BBB. Thus, we provide insights to uncover how a
compromised BBB may lead to SAE or permanent brain dysfunction in sepsis survivors.

Sepsis is a debilitating systemic inflammatory process involving multiple organ systems that is preceded by an infection. It
is the 10th leading cause of death in the United States with an
annual financial burden for patients and survivors that exceeds
$20 billion.1 Through mechanisms that remain largely poorly
understood, sepsis can induce acute and chronic changes in the
central nervous system (CNS), particularly at the blood-brain
barrier (BBB). A compromised CNS can lead to sepsis-associated encephalopathy (SAE), a well-characterized state of cognitive impairment and neurological dysfunction often seen in
*Current address for Afroz S Muhammad and Jessica Griffith:
Department of Pharmaceutics, College of Pharmacy, University of
Minnesota, Minneapolis, MN, USA.
†Current address for Brandon P Lucke-Wold: Department of
Neurological Surgery, University of Florida, Gainesville, FL, USA.

Sepsis Pathophysiology
Clinical sepsis presentation
The current definition from the Sepsis-3 consortium describes
sepsis as a life-threatening organ dysfunction caused by a
dysregulated host response to an infection.4 The most common precipitating sites for sepsis are the respiratory system,
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Figure 1. Comparison of the past and present guidelines for diagnosis of sepsis and septic shock. (A) Past guidelines stressed that the diagnosis and
progression of sepsis from a systemic inflammatory response to multiple organ dysfunction was sequential rather than multifactorial. (B) The current
guidelines for defining sepsis and septic shock stress that multiple linked considerations are necessary for an accurate diagnosis. Both the past and
present guidelines involve a clinical screening tool for patients likely to have sepsis that includes a clinical characterization of the severity of the disease.
Clinicians have traditionally used a Sequential Organ Failure Assessment (SOFA) system to categorize the severity of organ dysfunction in sepsis, which
associates a higher SOFA score with increased mortality.4,6 New sepsis guidelines employ a quick Sequential Organ Failure Assessment (qSOFA) score,
which is a modified version of the SOFA score that includes altered mental status, a systolic blood pressure ⩽ 100 mm Hg, and a respiratory rate ⩾ 22/min.
Patients with a qSOFA score ⩾ 2 have an overall in-hospital mortality risk greater than 10%.4,7 If warranted, further clinical analysis can be completed
using other SOFA criteria.4
Source: Adapted from Singer et al.4

genitourinary system, and the abdomen. Sepsis may present as
a combination of various non-descript signs and symptoms
making early diagnosis difficult. For example, patients may
present with fever, cold, pain, delirium, increased heart rate,
shortness of breath, diarrhea, and/or low blood pressure. The
diagnosis and management of sepsis has changed dramatically
over 30 years. The historical definition of sepsis was focused
primarily on inflammation and incorrectly portrayed sepsis as
a sequential process that eventually ends in septic shock
(Figure 1A). In 2016, Sepsis-2 criteria were revised to current
Sespis-3 criteria to improve consistency in classification in
epidemiological and clinical trials. The revised Sepsis-3 classification shown in Figure 1B focuses on accelerated recognition and management of sepsis.5
In recent years, the focus in clinical treatment has shifted to
severe sepsis and septic shock, which has increased survival in
hospitalized patients diagnosed with severe sepsis and critically ill patients with septic shock who have a higher risk of
multi-organ failure complications and death.8 This heterogeneous presentation of clinical sepsis makes disease management
and appropriate therapeutic interventions difficult. Some
challenges associated with the management of sepsis include
late diagnoses, poor prognoses, inadequate therapeutics, and

post-sepsis complications. These challenges stem from late
recognition and difficulties associated with differentiation of
sepsis from other illnesses in its early stage. In the later stages
of sepsis, recognition becomes easier, yet sepsis is more difficult to treat and often coincides with multi-organ failure.5,8,9
Most sepsis cases are hospital acquired and are often
comorbid with prior injury, such as stroke, trauma, or postsurgery. Most cases of hospital-acquired sepsis are treated in
the intensive care unit (ICU). However, ICU heterogeneity
can make sepsis more common in one ICU versus another. For
example, there is a higher incidence of sepsis in a trauma ICU
as opposed to a surgical ICU.8 Alternatively, a significant
number of sepsis patients are admitted to the hospital or
directly to the ICU via the Emergency Department (ED);
most of these patients present with community-acquired sepsis from pneumonia or complications from other comorbid
conditions such as diabetes.10,11 In addition to the patient setting, the development of sepsis often depends on several risk
factors, such as age, where a proportionate relationship exists
between increasing age and sepsis acquisition.12,13 Male sex,
non-white ethnicity, and preexisting conditions such as
Alzheimer disease (AD), HIV, or cancer are also risk factors
for acquisition.8,13–15
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Current experimental animal models of sepsis
Understanding the mechanisms involved in the pathophysiology of sepsis requires the use of animal models that adequately
reproduce several features of the human disorder including
both inflammation and infection. The most common animal
models are cecal ligation and puncture (CLP), the colon
ascendens stent peritonitis (CASP) model, endotoxin injection, and bacterial infusion.16 The CLP model is regarded as
the gold standard for human-like sepsis progression in animal
models.17 Execution of this model necessitates leakage of polymicrobial feces into the peritoneum after the cecum is punctured with a needle. Disease severity is modeled by controlling
needle size and number of punctures; however, a major limitation of this model is the failure to maintain continuous fecal
leakage due to abscess formation and necrosis of the punctured bowel. Some investigators also administer antibiotics
either at the time of injury or at intervals post injury. Although
antibiotic administration is an additional feature which mimics the treatment regimen in human patients, the use of different antibiotic classes and dosing paradigms across laboratories
may confound the interpretation of findings when results are
compared between laboratories.16,18 The CASP model is a
newer model recently introduced to counter the flaws of the
CLP model.16,19 The model involves the insertion of a stent at
the ascending portion of the colon, allowing continual leakage
of feces into the peritoneum.16,20 Despite resemblance to
human-like sepsis progression, the drawbacks to this model
include animal variation in colon size, fecal content, and the
volume of feces that leaks into the peritoneum.16,21 Although
these two models have provided remarkable insights to understand the pathophysiology of sepsis in humans, they fail to
fully recapitulate the comprehensive clinical progression of
sepsis in humans.16
Two alternative sepsis models involve injection or infusion
of endotoxin or bacteria. The endotoxin model typically
involves injection of lipopolysaccharide (LPS) endotoxin, a
component of Gram-negative bacterial cell walls which signals
most commonly through toll-like receptor-4 (TLR4).
Administration of LPS via different routes (ie, intraperitoneal,
intravenous, or intracerebroventricular) initiates a cytokine
storm that results in the release of tumor necrosis factor alpha
(TNF-α) and numerous interleukins (ILs; IL-1, IL-6, and
IL-10). Injection of LPS mimics many classical signs and
symptoms of sepsis-induced inflammation, thereby providing a
basic understanding of how inflammation activates the immune
response in sepsis.16,22 One major limitation of the LPS model
is the lack of integration of the infection component. A second
limitation is that very large endotoxin doses are required in
many rodent models to mimic the pathological profile of the
clinical sepsis picture observed in humans.23 Bacterial injection
is a less widely used model involving infusion of a bacterium,
usually Escherichia coli or Staphylococcus aureus, to initiate both
inflammation and infection.16,24,25 Different bacterial strains
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used for infection present a challenge in this model, as they will
produce different patterns of sepsis progression.26 Thus, the
characteristics of the sepsis model must be considered when
interpreting the effects of sepsis on the CNS and other organ
systems.

The CNS in sepsis: sickness behavior and SAE
A critical role for the CNS in the pathophysiology of sepsis has
emerged over the past 2 decades. Several recent reviews address
this topic in excellent detail.13,27–30 One important contribution
of the CNS is “sickness behavior.” Sickness behavior is a
response seen in sepsis characterized by fever, adaptive behavioral changes, and neuroimmune changes.31 The response is
governed primarily by systemic interactions with the vagus
nerve (VN) and circumventricular organs (CVOs). The VN is
an important mediator of inflammation. Septic mice that
underwent a vagotomy (VGX) surgery exhibited an increase in
the synthesis of inflammatory cytokines compared with sepsisonly mice.27,32–34 In contrast, stimulation of the VN in septic
animals resulted in an overall reduction in the synthesis of
inflammatory cytokines, leukocyte recruitment, and endothelial activation.34–36 The VN also relays peripheral information
to the medullary autonomic nuclei, whereas the CVOs may
serve as sensors for inflammatory mediators, primarily
cytokines, and serve as the foci for neuroimmune communication between the peripheral circulation into the brain parenchyma. Many of these neuroimmune communication circuits
are well described, but the underlying mechanisms that regulate these pathways remain poorly understood.37,38 For example, activation of the nucleus tractus solitarii and locus coeruleus
by inflammatory mediators subsequently activates autonomic
nuclei, behavioral, and neuroendocrine centers.39,40 The summative effect can be observed as depression, social withdrawal,
increased heart rate, poor blood pressure control, or altered
vigilance.18
In addition to sickness behavior, patients with acute sepsis
may have changes in brain function that present as delirium,
seizures, psychological disorders, abnormal motor movements,
and increased mortality.39,41 Changes in brain function are
most commonly manifested as delirium. Whereas sepsis-associated delirium usually presents as decreased activity, a hyperactive form associated with agitation may be seen in some
patients.39 Tools that can be used to confirm sepsis-associated
delirium include medical history, blood chemistry, electrolyte
balance, the ICU screening checklist, Confusion Assessment
Method, and Glasgow Coma Scale.39,42 Sickness behavior and/
or delirium may progress to a more severe phenotype, SAE,
which is regarded as a diagnosis of exclusion.43 It is characterized by impaired consciousness, seizures, delirium, coma, focal
cognitive deficits, and alterations in electroencephalogram
(EEG) patterns.44 Patients with SAE have increased mortality,
long-term neurological decline, memory lapse, inattentiveness,
disorientation, and verbal difficulties.45
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Alterations in EEG wave patterns often predict SAE outcome, and EEG reactivity is associated with mortality even at
1 year post severe sepsis.44,46 For example, a recent study showed
resting-state EEG changes in sepsis survivors at 6 to 24 months
after hospital discharge, including increased delta and sigma
activity compared with control patients.47 Changes in EEG
frequencies can be associated with changes in brain function.
For example, slowing alpha activity with increased theta activity reflects cortical dysfunction and can occur in patients with
mild to moderate encephalopathy. Slowing of delta activity is
often associated with more severe neurocognitive decline and
indicates impaired function in deeper brain structures, such as
the basal ganglia.44 Whereas the evaluation of EEG can be
sensitive to SAE diagnosis in the absence of neurological
examination abnormalities, it has poor specificity and can be
hampered by sedation and analgesia.45,48
Ischemia is another common complication of early sepsis
due to drastic changes in systemic blood pressure.41 A number
of human clinical studies support the premise of decreased cerebral blood flow (CBF) in acute sepsis.49–52 The abrupt change
in blood pressure with added sepsis-associated coagulopathy
causes reduced blood flow to neurons. The hippocampal region
and watershed areas are affected more often than other brain
regions when this occurs. Autopsies in patients who died from
septic shock revealed consistent ischemic and hypoxic insults in
areas particularly susceptible to low blood flow (eg, amygdala,
frontal junctional cortex, etc) and in autonomic centers.53
Furthermore, the autopsies of 7 delirious ICU patients in
another study revealed pathological lesions in the hippocampus, striatum, and pons triggered by ischemia or hypoxia.54 The
presence of ischemia in post-mortem studies strongly suggest
that vascular irregularities and alterations of CBF occur during
sepsis. Importantly, multiple clinical observations support the
concept that, in the absence of cerebrovascular occlusion (ie,
stroke), impaired cerebral autoregulation and hypotension may
be the primary drivers of tissue hypoxia and cerebral ischemia
observed in sepsis patients.55–57
A recent study in rats conducted by Towner et al58 showed
that CBF in the thalamus and cortex is significantly increased
24 hours post LPS injection but significantly reduced 6 weeks
post LPS injection when compared with saline controls.
Preceding human clinical studies also support the decrease in
CBF at 24 hours observed by Towner and colleagues, yet there
remains a paucity of literature on how sepsis may affect longterm CBF in human patients. Overall, coincident alterations in
cerebral blood and cardiovascular collapse in sepsis emphasize
the importance of fluid resuscitation as a crucial component
of sepsis management. The ideal type of fluid (colloid vs
crystalloids) and ideal composition used to treat septic patients
remains controversial. A total of 3 clinical trials demonstrated
that colloid use in sepsis treatment failed to show a clear
benefit.59–61 In addition to the findings from this study, the
restricted accessibility, safety issues, and the expensive value of

Journal of Central Nervous System Disease 
colloids shifted the debate toward identifying the ideal crystalloid composition (eg, Ringer lactate, Ringer acetate, etc).62 We
refer the reader to excellent reviews regarding optimal fluid
therapeutic strategies in sepsis.62–64
The utilization of magnetic resonance imaging (MRI) in
the diagnosis of SAE offers a unique opportunity in capturing
some of the morphologic, ischemic, and metabolic alterations
associated with sepsis. A summary of MRI findings in acute
sepsis is shown in Table 1. In particular, diffusion-weighted
imaging (DWI) and the apparent diffusion coefficient (ADC)
are 2 MRI modalities currently used in assessing BBB breakdown caused by vasogenic (extracellular) or cytotoxic (intracellular) edema.73 Cytotoxic edema typically caused by ischemia,
hypoxia, or vasogenic edema is the most consistently reported
MRI change associated with SAE.73–76 Early detection of BBB
breakdown by gadolinium (Gd) could establish an adequate
therapeutic window for current and future septic treatments,
but human studies are limited.77–79 A recent study in rats
revealed a significant increase in the infiltration of Gd in the
cortex, hippocampus, and thalamus 24 hours and 1 week post
LPS injection.58 Gd use may also cause a substantial risk of
nephrogenic systemic fibrosis, a risk factor which suggests that
Gd-based imaging in the CNS should be evaluated on a caseby-case basis.
Sedatives are often administered in the ICU when treating
sepsis. A study conducted by Qiao et al80 in rats showed that
the application of dexmedetomidine and midazolam improved
survival and reduced cytokine levels and splenic apoptosis in
septic mice. Another systematic review by Zamani et al81
emphasized the importance of the kind of sedative used in
treating sepsis; the findings from this study revealed that dexmedetomidine improved short-term mortality when compared
with other sedatives. It is widely thought that the neuroprotective effects of dexmedetomidine result from neuronal death
prevention, suppression of inflammatory cytokines, and modulation of neurotransmitters released in the sympathetic nervous
system.81–84 However, a limitation noted by Zamani et al was
the small sample size included in the clinical studies. It is
important to note that the tools used in the confirmation of
sepsis-associated delirium are not helpful in ICU-sedated
patients who may otherwise exhibit signs of delirium.43
Sepsis also affects long-term neurological outcomes. The
greatest risk factor for long-term impairment is the duration of
delirium in the acute phase of sepsis and the increased ventricle-to-brain ratio as calculated by MRI.39,41,85,86 A seminal
study published by Iwashyna et al87 suggested that up to 70%
of sepsis survivors may exhibit lasting neurological impairment,
including alterations in mood, cognition, and motor function.
Cognitive, motor, and mood impairments are three of the most
common long-term neurological outcomes in septic patients.41
Current evidence also suggests an increased susceptibility to
other neurodegenerative disorders such as stroke or AD post
sepsis insult.88 Thus, patient populations that are the most
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Table 1. MRI imaging studies in patients with sepsis.
Publication

Subject

Acute MRI findings

Hollinger et al65

Adult human

T2-weighted hypersensitivity with altered DWI showing ring enhancement

Sharshar et al66

Adult human

Multiple ischemic strokes with predominant white matter lesions

Jackson et al67

Adult human

Bilateral diffuse hyperintense areas in the white matter of the cortex and
cerebellum

Kondo et al68

Pediatric
human

Restricted diffusion in the basal ganglia and subcortical white matter of the
frontal and occipital lobes; brain edema was also present

Morandi et al69

Adult human

White matter hyperintensities (WMHs)

Bozza et al70

Rodent

Accumulation of the vasogenic edema fluid at the base of the brain

Suchyta et al71

Adult human

Atrophy, WMH, edema, and localized bilateral hemorrhage in the cortex and
subcortical structures

Polito et al57

Adult human

Leukoencephalopathy and ischemic stroke

al72

Adult human

Acute abnormal hypointensity of the white matter and edema; subacute WMH

Rodent

Increased MRI intensities in the cortex, Perirhinal cortex, and hippocampus;
increased gadolinium infiltration into various brain regions

Luitse et

Towner et al58

DWI, diffusion-weighted imaging; MRI, magnetic resonance imaging.

Table 2. BBB cell types affected by sepsis and consequential outcomes.
Cell types

Cellular pathology

Consequences

Refs

Astrocytes

Astrogliosis

Increased BBB permeability
Neuroinflammation

90–94

Endothelial
cells

Endothelial activation

Increased BBB permeability
Microthrombus formation
Ischemia

95–97

Microglia

Microgliosis

Increased iNOS expression
Neuroinflammation
Cytokine production

98–100

Pericytes

Unknown

Increased BBB permeability

101,102

Neurons

Excitotoxicity and neuronal dysfunction

Cognitive dysfunction

87,103–106

BBB, blood-brain barrier.

vulnerable to long-term neurologic decline post sepsis are
the elderly and patients with preexisting neurodegenerative
diseases.12,13,39,88 The consequences of sepsis on both acute and
chronic neurological outcomes demonstrate a critical need to
understand the mechanisms involved in SAE development.
Harnessing this knowledge will provide essential therapeutic
avenues to limit SAE progression and protect against longterm neurological impairment or dysfunction. The remainder
of this review will focus on the role of the BBB in sepsis-associated cognitive dysfunction, as preclinical and clinical investigations have uncovered 3 primary BBB-linked mechanisms
that contribute to the cause of SAE and the associated shortterm and long-term cognitive dysfunction: (1) activation of
neuroinflammation, (2) microcirculatory dysfunction, and (3)
increased neuronal excitotoxicity.39,89

Mechanisms of BBB Dysfunction in Sepsis
BBB overview
This section will provide a brief overview of the cell biology
and physiology of the BBB, as the focus of this review is the
BBB in sepsis. BBB and other associated cell types within the
neurovascular unit that are affected by sepsis are shown in
Table 2.39,107 The BBB is a highly selective, dynamic, and semipermeable biological interface between the brain parenchyma
and cerebral circulation. Preservation of BBB integrity protects
normal brain function and is dependent on maintaining a precise cerebral homeostasis driven, in large part, by ion and gas
concentrations and nutrient availability. The BBB’s unique
structure is composed of endothelial cells, astrocytes, pericytes,
and a basal lamina. The endothelial cells are joined by tight
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junctions (TJs), and surrounding pericytes and astrocytes,
which associate with the basal lamina to protect the brain
parenchyma. Endothelial cells are sealed or joined together by
TJs which are composed of occludin, claudin, and cadherin
proteins. Because paracellular movement of compounds around
and between endothelial cells is highly restricted, active transport is required to move polar solutes and nutrients across the
BBB into the brain parenchyma.108 However, water, small
gases, and small- to moderate-sized lipid-soluble compounds
can enter the brain passively.109,110 Primary efflux transporters
include permeability glycoprotein (P-gp) and breast cancer
resistance protein (BCRP), which actively pump compounds
out of the brain and back into circulation.108 Often, these
transporters further restrict the permeability of compounds
and drugs which may otherwise have the molecular characteristics to passively cross the BBB.111 Readers are referred to
many excellent reviews on the BBB for a more in-depth discussion of these and other topics pertaining to the BBB.37,88,109,112,113

Neuroinflammation and BBB permeability
A probable starting point of sepsis-induced acute brain dysfunction is the initiation of neuroinflammation, but the mechanism by which this occurs is not well understood.51
Neuroinflammation is a response to CNS disruption or dysfunction and is typically found in all neurological disorders.114
Current literature suggests that neuroinflammation in sepsis
begins when immune cells recognize foreign pathogen-associated molecular patterns (PAMPs) such as LPS, flagellin, fimbriae, peptidoglycan, heat shock proteins, and DNA fragments,
which are encoded as “danger signals” to the host. Recognition
of PAMPs causes the release of proinflammatory cytokines in
the periphery.115 Inflammatory mediators may enter the brain
by numerous mechanisms that include transcellular diffusion,
solute carrier proteins, receptor-mediated transcytosis, and
adsorptive transcytosis.37 Many cytokines enter the brain
through receptor-mediated endocytosis on brain endothelial
cells. For example, during inflammation, TNF-α is upregulated
and its transportation from blood to brain parenchyma is
increased, primarily through receptor-mediated endocytosis of
its receptors, tumor necrosis factor receptor 1 (TNFR1) and
tumor necrosis factor receptor 2 (TNFR2).116,117 Molecules
originating in peripheral or CNS tissues may activate vascular
endothelium and various leukocytes to produce hormones that
facilitate their entry into the brain. For example, Nishijima
et al118 observed that prostaglandin E2 enhanced transport of
serum-insulin-like growth factor 1 across the BBB.
Cytokine production contributes to neuronal dysfunction in
sepsis in addition to many other neurological disorders.
Cytokine infiltration enhances the activation of endothelial
cells and microglia, which ultimately leads to loss of neuronal
function. Activation of the endothelium leads to enhanced
activity of the coagulation cascade, microthrombus formation,
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and ischemia, which, in turn, promotes increased BBB permeability and leukocyte infiltration. This process triggers neuronal
damage, apoptosis, and brain edema.119,120 Cytokine-mediated
microglial activation occurs simultaneously with endothelial
cell activation. Although the normal microglial response is to
phagocytose-injured neuronal cells and clear debris, sustained
and dysregulated microglial activation is highly detrimental to
specific regions of the CNS. Thus, persistent microglial activation enhances the production of inflammatory cytokines and
reactive oxygen species (ROS), which perpetuates a vicious
cycle of increased BBB permeability coupled with neuronal
damage and apoptosis.116,119 Collectively, neuronal apoptosis
and microglial activation are 2 primary mechanisms that
increase the activity of inducible nitric oxide synthase (iNOS)
activity and generation of nitric oxide (NO). Neuronal apoptosis is further exacerbated due to neuronal sensitivity from
increased levels of NO produced by activated microglia.121,122
Intriguingly, iNOS levels are elevated in sepsis and are highest
in deceased septic patients.70,100 This increased iNOS activity
could also be responsible for the cardiovascular collapse seen in
sepsis.53,100,117 It is likely that this cardiovascular collapse also
affects the cerebral microcirculation and leads to subsequent
sepsis-associated brain dysfunction.
Sepsis, particularly Gram-negative sepsis, has been shown
to upregulate caveolin-1 at the endothelial membrane.123
Increased caveolin-1 has recently been shown to increase
the amount of peripheral immune infiltration into the brain.124
The mechanisms by which this occurs are not completely
understood, but new preclinical studies have shed light on
some prevailing theories. Wu et al125 found that caveolin-1
facilitates T-cell trafficking into the CNS via intercellular
adhesion molecule 1 (ICAM-1)-mediated signaling. Caveolin-1
causes acid sphingomyelinase to interact with ICAM-1
increasing the binding affinity for peripheral immune cells.126
Once activated, ICAM-1 facilitates peripheral immune cell
diapedesis into the brain. This process occurs via Src phosphorylation within endothelial cells and a subsequent conformational change to ICAM-1, which directly induces the
transcellular migration.127 The leaky BBB enhances the entire
process during sepsis. After entering the brain, T cells are
recruited toward damaged glia via cytokine release. Recent evidence suggests that IL-17A aids this migration process.128 In
addition, T cells are helped by astrocytes to re-cross the leaky
BBB and carry information about the status of the brain to the
rest of the body.129 It is postulated that the peripheral immune
cells also release cytokines that maintain the leakiness of the
BBB as they exit the brain. When and how long this cross-talk
between microglia and peripheral immune cells persists remains
to be elucidated. The feedback loop has, however, been implemented in non-autonomous neuronal death.130 The brain
regions most susceptible are the nigra-striatal pathway and
hippocampus.131 Future studies are warranted to further characterize the brain/immune communication network and, in
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Figure 2. Complex neuroinflammatory processes promote BBB dysfunction in early sepsis which enhance neuronal dysfunction and trigger cognitive
impairment. Highly complex and multifactorial mechanisms transduce systemic inflammatory signals to the brain in early sepsis, resulting in neuronal
dysfunction and subsequent acute and chronic cognitive impairment. The BBB serves as both a nexus and an interface for these signals. Sepsis begins
with systemic infection that evokes an exaggerated host immune response from the recognition of pathogen-associated molecular patterns (PAMPs).132 In
this example, sepsis is triggered by a local lung infection (eg, pneumonia). Systemic proliferation of the infection initiates a hyperinflammatory response
that stimulates the production of immune cells, cytokines, and other inflammatory mediators. These inflammatory mediators initiate a cascade of events
that either directly or indirectly impact the peripheral microcirculation via cardiovascular autonomic alterations, or activation of the coagulation cascade,
and converge on cerebral microvessels and their component BBB endothelial cells. Cerebral hypotension and microthrombus formation also initiate
ischemia. The convergence of these events lead to BBB dysfunction, including immune cell infiltration, upregulation of adhesion molecules, increased
BBB permeability, activation of cerebral cytokines, cerebral edema, and enhanced neuroinflammation. 2,37,88,121 Positive feedback of the disrupted BBB on
neuroinflammation and potential amplification of this feedback is indicated by the solid bidirectional arrow (direct feedback) and the dotted arrow (indirect
feedback).
BBB, blood-brain barrier; CP, choroid plexus; CVOs, circumventricular organs; eNOS, endothelial nitric oxide synthase; iNOS, inducible nitric oxide synthase; NO, nitric
oxide.

particular, where the peripheral immune cells ultimately reside
after exiting the brain. Collectively, these mechanisms represent the complicated and multifactorial mechanisms that must
be involved in sepsis at the BBB. An integrated overview of the
brain and peripheral mechanisms found in acute sepsis is
shown in Figure 2.

Mitochondrial dysfunction
Mitochondrial dysfunction is a common consequence of sepsis. It has been described in a number of studies with substantial evidence pointing toward oxidative stress as a
contributing factor. This literature is summarized in several
excellent reviews.133–136 The abnormality in the function of the
mitochondria plays a role in the development of post-sepsis
behavioral, psychological, and cognitive dysfunctions such as
SAE.137–139 At the cellular level, reactive nitrogen species
(RNS), like NO, and ROS, such as peroxynitrite (ONOO−),
inhibit complexes I and IV of the electron transport chain (ETC).
This inhibition produces a subsequent decrease in oxygen

consumption and permits the buildup of O2− species and the
eventual leakage of this species across the ETC along with
other ROS/RNS.140–142 The leaked species activate uncoupling
proteins that cause an increased H+ (proton) permeability
from the inner mitochondria into the mitochondrial matrix to
form oxide ions. Ultimately, these ions are converted to water
without any adenosine triphosphate (ATP) generation.143 This
process may seem to decrease the number of reactive species
from the reaction described above, but the downside of continual proton leakage is an induction of cytopathic hypoxia, a
condition whereby mitochondria are unable to use oxygen irrespective of the presence or absence of oxygen.144 In addition to
cytopathic hypoxia, ONOO− causes single-strand DNA breaks
at the genomic level; this further exacerbates mitochondrial
dysfunction because of the high reliance of oxygen in the reparative process of the damaged DNA.145 Also, some ROS/RNS
enhance both endoplasmic reticulum and mitochondrial membrane permeability, which permits the leakage of calcium and
proapoptotic proteins into the cytoplasm.146–148
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The course of infection, type and amount of ROS/RNS,
and the brain regions where oxidative stress occurs are important when investigating the timing of oxidative damage leading
to mitochondrial dysfunction. Recent studies in rats using
thiobarbituric acid and protein carbonyls as markers of lipid
and protein oxidation, respectively, have suggested that lipid
peroxidation is consistent and widely distributed in the hippocampus, cerebellum, and cortex 6 hours post CLP, whereas
oxidative damage due to protein oxidation was largely restricted
to the hippocampus. Investigators also identified a concomitant imbalance in the antioxidant enzymes superoxide dismutase (SOD) and catalase (CAT). They found that the SOD
activity increased in the first 6 hours post sepsis, whereas both
SOD and CAT activity levels were decreased compared with
sham-injured mice at 12 to 96 hours.138 Taken together, these
findings suggest that oxidative damage in the CNS occurs
much earlier than expected in sepsis. Expanding on these findings, Barichello et al used N-acetylcysteine (NAC) and deferoxamine (DFX) antioxidants as a therapeutic intervention in
male rats at 6 hours post CLP. They found that the combined
administration of NAC and DFX reduced oxidative hippocampal damage, but not when administered separately.149
These results further emphasize the importance of all CNS
antioxidant systems and signify that multiple targets are
required for adequate therapeutic efficacy in sepsis.
Overall, the systemic immune response in sepsis accelerates
the increased generation of ROS/RNS, which, in turn, promotes lipid peroxidation in the cerebrovasculature and brain
parenchyma. The continued assault from the periphery perpetuates a vicious cycle of ROS/RNS generation between the
brain and the periphery. As the overproduction of ROS/RNS
overwhelms the capacity of the antioxidant system, the end
results manifest as neuroinflammation, ischemia, and increased
BBB permeability. Most importantly, the vicious cycle promotes an impaired oxidative metabolism which persists
throughout the duration of sepsis and likely continues after
recovery.150 Thus, sustained production of ROS/RNS after
recovery is hypothesized to be another mechanism that contributes to long-term neurological impairment post sepsis.

Putative role of tissue non-specific alkaline
phosphatase at the BBB
The identification of unexplored membrane proteins may be
key to better understanding the specific barrier functions of the
BBB in disease states such as sepsis. In turn, this knowledge
may provide novel therapeutic targets for intervention. One
potential therapeutic target localized primarily to the surface of
brain endothelial cells is the non-specific isoform of alkaline
phosphatase (AP). The enzyme AP has been shown to play an
integral role in the regulation of inflammation and can be found
either as a soluble form in the peripheral circulation or as a
membrane-bound form on brain endothelium, as well as
numerous other cell types in the periphery. There are 4
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isoforms of AP in humans encoded by 4 separate genes (gene
names are in italics): intestinal alkaline phosphatase (IAP;
ALPI), placental alkaline phosphatase (PLAP; ALPP), germinal
alkaline phosphatase (GCAP; ALPPL2), and tissue non-specific alkaline phosphatase (TNAP; ALP).151,152 TNAP, also
known as bone/liver/kidney AP, is the most abundant AP isoform in humans and rodents. TNAP is the only isoenzyme of
AP detected in the human brain and has long been used as a
marker of brain endothelium, although its presence has also
been detected in neurons.153,154
The cellular and molecular mechanisms underlying TNAP’s
functional role in brain endothelium and BBB are unclear;
however, results from numerous studies across several species
strongly suggest that TNAP plays a role in the transport of
specific classes of compounds across the BBB.155 Brain
endothelial cell TNAP protein may also help facilitate crosstalk between the BBB and other cell types; in addition, a number of molecules, including cyclic adenosine monophosphate
(cAMP) and IL-6, have been shown to modulate TNAP
expression. Deracinois et al153 found that TNAP expression
was increased in brain endothelial cells, and that the inhibition
of AP activity using levamisole, a non-specific AP inhibitor,
increased brain endothelial cell permeability. We speculate that
TNAP’s regulatory phosphatase activity on a number of BBB
endothelial proteins may play an important role in maintaining
BBB integrity, thereby alleviating septic encephalopathy or
long-term brain dysfunction. As shown in Figure 3 of our in
vivo study, TNAP enzyme activity appears to be upregulated in
CLP-injured mice compared with their sham-injured counterparts. However, the mechanistic function of TNAP in the BBB
remains to be elucidated in sepsis and is currently being investigated in our lab.
Other brain-specific functions of TNAP have been
described as having a role in proliferation and migration in the
developing nervous system, control of axonal growth formation
and maturation of synapse, and dephosphorylation of extracellular phospho-tau in AD.154,157–159 Despite the absence of a
clearly elucidated mechanism for TNAP in brain endothelium
and neurons, emerging data suggest that the manipulation of
the AP activity can influence disease outcomes. For example,
pretreatment of experimental autoimmune encephalomyelitis
(EAE) mice with bovine intestinal AP reduced the disease severity through a mechanism that caused a reduction in neuroinflammation and autoreactive T regulatory cell proliferation.160
Increased levels of AP have also been detected in blood of epileptic patients, suggesting its applicability as a potential biomarker for many neurological diseases.161

Pharmaceutical Interventions in Sepsis
Antimicrobial delivery across the BBB
There is a current shift in the literature regarding specific pathogens that play a role in the inflammatory response associated
with sepsis. Knowing the microbe implicated in sepsis best
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Figure 3. Alkaline phosphatase (AP) activity in the brain and BBB. (A) Histological staining for AP activity shows decreased TNAP enzyme activity in the
cortex of septic male mice (10-15 months old) subjected to the cecal ligation and puncture (CLP) model of experimental sepsis. C57BL/6J mice were
subjected to CLP or a sham injury and brains were harvested 24 hours later. (B) Graph shows the quantification of cortical AP enzyme activity in CLP
(n = 3, 52.49 ± 0.1094) versus sham (n = 3, 53 ± 0.1142) mice (sections = 3 per mouse; data represented as mean ± SEM, *P < .05, t(4) = 3.384, unpaired
Student’s t-test, scale bar = 115 µm). AP activity was assessed in 35-µm brain sections with the BCIP/NBT AP Substrate Kit (Vector Laboratories,
Burlingame, CA) following previously published methods.156
BBB, blood-brain barrier; TNAP, tissue non-specific alkaline phosphatase.

dictates which appropriate antibiotic or other type of treatment
is required. Whereas older studies implicate Gram-negative
bacteria necessitating antibiotic intervention in sepsis, newer
studies have begun to reveal that other pathogens like Grampositive bacteria, fungi, and viruses can also stimulate the
inflammatory response associated with sepsis. According to
recent epidemiologic studies, Gram-positive bacteria cause
approximately 50 000 more cases of sepsis every year in the
United States compared with Gram-negative bacteria.8,14,162
Because factors such as the type of inciting pathogen and the
site of infection are good predictors of patient mortality, it is
essential that the antimicrobial agent be used to effectively
treat the disease as well as any subsequent side effects such as
neurological impairment. Currently, this is often difficult and
impractical in the hospital, as the time from diagnosis to initiation of treatment is critical. In addition, the sepsis field has
faced many difficulties in developing effective therapeutics to
treat sepsis. Currently, there are no Food and Drug
Administration (FDA)-approved drugs used to treat sepsis as
there have been numerous clinical trial failures over the past
15 years.163–166 This difficulty stems from our incomplete
knowledge about the mechanisms that underlie the disease
pathology associated with sepsis.

Initial suspicion of sepsis necessitates the use of non-specific broad-spectrum antibiotics against Gram-positive (eg,
vancomycin) and Gram-negative (eg, imipenem) bacteria
before blood cultures become available. Following pathogen
identification, the initial antibiotic regimen is often narrowed
to a single agent.45,167 Although numerous human and animal
studies have shown an increase in survival following antibiotic
administration, limited published data are available on whether
or how antibiotics are able to penetrate the BBB. More importantly, the effects of antibiotics and other antimicrobials on
brain function and sepsis-associated neurological impairment
are not well studied.168–173 Thus, a complete knowledge of drug
mechanisms in the CNS is essential for identifying an appropriate drug regimen and therapeutic approach to treat the neurological impairment associated with sepsis.174,175
The most common drug classes used to treat sepsis are
shown in Table 3. Drugs belonging to the fluoroquinolone and
sulfonamide classes, along with rifampin, metronidazole, and
chloramphenicol, readily enter the brain regardless of disease
state. Antimicrobials that do not normally penetrate the brain
may readily cross into the BBB, or into the cerebrospinal fluid
(CSF), due to opening of TJs and reduced P-gp activity.186 In
contrast, more hydrophilic and larger drugs such as vancomycin
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Table 3. Antimicrobials used in sepsis treatment and their corresponding CNS penetration.
Drug class

Example(s)

Lipophilicity

CNS penetration

Refs

β-lactam

Penicillin, piperacillin

++

++

176,177

Fluoroquinolones

Ciprofloxacin, moxifloxacin

+++

+++

178

Tetracyclines

Doxycycline

−−

0

179

Glycylcycline tigecycline

−−

++

180

Glycopeptides

Vancomycin

−−

+

181

Anti-tuberculosis

Pyrazinamide, isoniazid

−

+++

182

Anti-fungal

Amphotericin B

−−

++

183

Anti-parasitic

Pyrimethamine, albendazole

++

+

184,185

CNS, central nervous system.
+indicates higher, − indicates lower, and 0 indicates neutral or no change.

and members of the β-lactam class of antibiotics do not readily
enter the CSF or brain unless the meninges are inflamed.187

Intravenous immunoglobulin administration
Active advancement in understanding the pathophysiology of
sepsis has led to the use of emerging immunomodulatory adjuvants to target septic encephalopathy. The acute phase of sepsis
is embodied by a diminished production of immunoglobulin G
(IgG) because the immune system takes 1 to 2 weeks to generate sufficient IgG levels needed to respond to an infection.188
Therefore, the observed reduction in IgG levels has warranted
the use of immunomodulatory intravenous immunoglobulins
(IVIgs) in sepsis patients.188,189 The mechanisms by which
IVIg operates are complex and remain unclear.190,191 However,
it has been proposed that the IVIg polyclonal IgG domains
exert an immunomodulatory function by binding Fc receptors
(FcγRs) found on many immune cell types (ie, microglia,
endothelial, leukocyte). IVIg binding is thought to neutralize
endotoxins/cytokines, inhibit complement activation, and
block leukocyte adhesion molecule binding.90,192,193
Several studies have demonstrated the efficacy of IVIg
treatment in sepsis. Esen et al193 showed that the administration of IVIg enriched with IgA and IgM improved BBB permeability, reduced sickness behavior, and improved mortality in
CLP-induced rats. Further investigations by the same group
revealed that the improvement in BBB integrity, neuronal
destruction, and amelioration of septic encephalopathy is
mediated by the inhibition of complement 5a (C5a).90 A small
number of clinical meta-analytical studies have reported a
decrease in mortality of sepsis patients administered IVIg; this
finding complements the results observed by Esen et al. 193,194–196
In contrast, a larger double-blinded randomized control trial
conducted in the International Neonatal Immunotherapy
Study (INIS) showed no significant differences in mortality

following IVIg administration.192,197 Note that the studies
included in the meta-analysis showing a decrease in mortality
after IVIg administration consisted of relatively small patient
populations, which suggests that these studies may not have
been sufficiently powered to detect meaningful differences in
mortality.191,192,198,199
Taken together, the apparent effects of IVIg in sepsis treatment appear to be promising yet inconclusive. The high cost of
treatment combined with unknown mechanism(s) of action
and limited efficacy in a number of publications have made it
difficult for organizations like the FDA and the Surviving
Sepsis Campaign Guidelines (SSCG) to recommend IVIg as
an adjuvant in sepsis treatment.188,190,192

Conclusions

The heterogeneous presentation and causes of sepsis are profoundly linked to its variable clinical outcomes. Chronic neurological impairment is an increasingly common yet poorly
understood clinical outcome. Understanding the mechanistic
determinants of BBB integrity during sepsis is critically important for sepsis diagnosis and implementation of treatment
options to ensure a positive prognosis. Importantly, long-term
prognosis in sepsis survivors is linked to both transient and
permanent alterations in BBB permeability and function. Thus,
targeting the BBB should be incorporated as part of a shortand long-term therapeutic strategy in all sepsis patients. The
development of therapies that inhibit BBB dysfunction and
stimulate normal BBB function will limit mortality, suppress
neuroinflammation, and improve neurological outcomes in
sepsis survivors. Equally important for effective sepsis treatment is a better understanding of how antimicrobials and other
drugs (eg, IVIgs or vasopressors) used in treating sepsis readily
cross the BBB, and whether there are any additional unknown
impacts on brain function. Taken together, the identification of
cellular and molecular mechanisms that preserve BBB function
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in the face of sepsis will provide valuable therapeutic targets to
treat numerous inflammatory disorders that target both the
brain and the periphery—ranging from AD and stroke to diabetes and cardiovascular disease.
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